Drug Database
Back to search

Netherlands· NL-5543443cb8ea

Daklinza 30 mg filmomhulde tabletten

A daclatasvir product containing daclatasvirdihydrochloride, registered in Netherlands by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 3 of our 19 countries.

ATC J05AP07

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedDaklinza 30 mg filmomhulde tablettenATCJ05AP07REGISTER NO.NL-5543443cb8eaPACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about daclatasvirdihydrochlorideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Daclatasvir is registered in 3 of 19 countries.

Countries holding a registration under ATC J05AP07 (daclatasvir), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 1 of them publish a price we can compare per daily dose
Search daclatasvir products by name

Daclatasvir · ATC J05AP07

3 / 19 countries

  • Finlandprice
  • Netherlands
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
DACLATASVIRDIHYDROCHLORIDE
Manufacturer
Bristol-Myers Squibb Pharma EEIG
Country
Netherlands (NL)
ATC code
J05AP07
ATC class
Daclatasvir
Defined daily dose
60 mg, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/14/939

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

123 interactions on record for daclatasvir.

Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check daclatasvir against other medicinesHow interaction checks work

Daclatasvir · interactions on record

123 records

  • 21 severe
  • 97 moderate
  • 5 minor

Most severe, free to view

  • EluxadolineA07DA06severe
  • EdoxabanB01AF03severe
  • DexamethasoneH02AB02severe
  • KetoconazoleH02CA03severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Daclatasvir in 3 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All daclatasvir products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d99fc8f1-4256-4647-a676-817257f4ff87
GET /v1/drugs/d99fc8f1-4256-4647-a676-817257f4ff87?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/daklinza-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Daclatasvir",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp114876",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "HYPROMELLOSE (E 464)",
    "IJZEROXIDE GEEL (E 172)",
    "INDIGOKARMIJN ALUMINIUMLAK (E 132)",
    "LACTOSE 0-WATER",
    "MACROGOL 400",
    "MAGNESIUMSTEARAAT (E 470b)",
    "SILICIUMDIOXIDE (E 551)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "DACLATASVIRDIHYDROCHLORIDE"
  ],
  "leaflet_url": null,
  "authorised_at": "2014/08/22",
  "procedure_number": "EMEA/H/C/003768",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/14/939",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about daclatasvir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console